296 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
is responsible for approximately $10.4 billion in direct costs for hospitalizations and outpatient visits for adults in the U.S. annually.
Oral CC-42344 … , including the genogroup II, genotype 4 (GII.4) norovirus strain that is responsible for major norovirus outbreaks.
In August 2023 we announced our
8-K
EX-99.1
vgjecxgcwg4acuwm6
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
8-K
EX-99.1
pfoqw6l
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-99.1
niumpohh132c
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
EX-99.1
iha1r5jgylu q3
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
8-K
r07zyqd 18
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
EX-99.1
1xnz5b4a2v4l
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am